Nonoperative management of giant omphalocele leading to early fascial closure
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Dec 2018 · 1 min read
In brief
In brief
Serial taping technique achieved early fascial closure in ten giant omphalocele patients (mean 13.7 days) without primary surgical repair, avoiding complications of staged approaches like multiple anesthetics and silo dehiscence. Six patients achieved primary closure without patch; four required temporary Gore-Tex with subsequent fascial closure.
Written by the GCMD Library team from the article.
Purpose
We describe our series of giant omphalocele patients treated with a serial taping method for gradual reduction of the abdominal contents and early fascial closure.
Methods
Between 2010 and 2017 we cared for ten newborns with giant omphaloceles. The average gestational age was 35.5 weeks (range 29–38) and average birthweight was 2.84 kg. Seven infants had other major anomalies, including one with a variant of Pentology of Cantrell. Four had abnormal chromosomes. None had any attempt to primarily close the defect. Omphalocele defects were serially taped at bedside in the NICU with the child awake until the viscera were completely reduced, and the defect could be closed.
Results
Mean time to closure was 13.7 days (median 14 days). Six were closed primarily without a patch. The remaining four infants required Gore-Tex patch (covered by skin) which was later removed and fascia closed in three infants (at 70 days, 75 days, and 11 months of age). Total length of stay was a mean 71.8 days (median 71).
Conclusions
Serial taping achieves early fascial closure and avoids complications of a staged surgical approach, such as multiple anesthetics, loss of fascial margin integrity, silo dehiscence, and fistula formation. Compression of the viscera is slow enough to avoid abdominal compartment syndrome and the fascia and amnion are left intact leaving the option available to use escharotic agents if required.
Type of study
Treatment study.
Level of evidence
Level III.